MedAdvisor (MDR.AX) Stock Price

MedAdvisor Price

🇦🇺CLOSED
0 AUD
Market closed
Today +/-
Today %

MedAdvisor (MDR.AX) Stock | ISIN AU000000MDR6. Revenue is 110.6 M AUD. Net income is 2.28 M AUD. MedAdvisor operates in the Health sector.

Over the last 14 years MedAdvisor grew revenue by 77.8% annually, reaching 63 M AUD. For MedAdvisor, the net margin of -95.6% is down versus -34.6% a few years ago.

MedAdvisor stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of MedAdvisor over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how MedAdvisor stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing MedAdvisor's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

MedAdvisor Stock Price History
DateMedAdvisor Price
Access this data via the Eulerpool API

MedAdvisor Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2011
20,000 AUD
-70,000 AUD
-70,000 AUD
Jan 1, 2012
120,000 AUD
-990,000 AUD
-990,000 AUD
Jan 1, 2013
90,000 AUD
-3.01 M AUD
-3.75 M AUD
Jan 1, 2014
30,000 AUD
-2.39 M AUD
-11.14 M AUD
Jan 1, 2015
1.4 M AUD
-1.04 M AUD
-546,100 AUD
Jan 1, 2016
1.76 M AUD
-2.86 M AUD
-3.07 M AUD
Jan 1, 2017
4.9 M AUD
-3.36 M AUD
-3.43 M AUD
Jan 1, 2018
7.39 M AUD
-4.44 M AUD
-4.45 M AUD
Jan 1, 2019
9.19 M AUD
-8.09 M AUD
-8.1 M AUD
Jan 1, 2020
11.07 M AUD
-9.66 M AUD
-9.59 M AUD
Jan 1, 2021
40.28 M AUD
-16.81 M AUD
-13.95 M AUD
Jan 1, 2022
67.75 M AUD
-16.19 M AUD
-17.35 M AUD
Jan 1, 2023
97.96 M AUD
-8.43 M AUD
-11.31 M AUD
Jan 1, 2024
98.4 M AUD
-432,800 AUD
792,100 AUD
Jan 1, 2025
63 M AUD
-13.06 M AUD
-60.21 M AUD

MedAdvisor Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 23, 2026, 10:07 AM
 
REVENUE (M AUD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M AUD)
NET INCOME (M AUD)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
202120222023202420252026e2027e2028e
4067979862110117116
263.6467.544.781.03-36.7377.426.36-0.85
5550.7560.8254.0851.6129.0927.3527.59
2234595332323232
-13-17-110-60250
44.4430.77-35.29-103.33150
316.51378.12544.96548.12565.56565.56565.56565.56
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales MedAdvisor generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue MedAdvisor retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare MedAdvisor's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares MedAdvisor has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against MedAdvisor's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

MedAdvisor stock margins

The MedAdvisor margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MedAdvisor. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MedAdvisor.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2011
52.25 %
-350 %
-350 %
Jan 1, 2012
52.25 %
-825 %
-825 %
Jan 1, 2013
52.25 %
-3,344.44 %
-4,166.67 %
Jan 1, 2014
52.25 %
-7,966.67 %
-37,133.33 %
Jan 1, 2015
54.85 %
-74.09 %
-38.88 %
Jan 1, 2016
78.3 %
-162.28 %
-174.25 %
Jan 1, 2017
85.03 %
-68.48 %
-69.97 %
Jan 1, 2018
88.89 %
-60.07 %
-60.24 %
Jan 1, 2019
88.97 %
-87.95 %
-88.12 %
Jan 1, 2020
88.97 %
-87.3 %
-86.58 %
Jan 1, 2021
56.64 %
-41.72 %
-34.63 %
Jan 1, 2022
51.65 %
-23.89 %
-25.6 %
Jan 1, 2023
60.64 %
-8.61 %
-11.54 %
Jan 1, 2024
54.38 %
-0.44 %
0.8 %
Jan 1, 2025
52.25 %
-20.73 %
-95.58 %

MedAdvisor Stock Revenue, EBIT, Earnings per Share

The MedAdvisor earnings per share therefore indicates how much revenue MedAdvisor has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2011
0 AUD
-0.01 AUD
-0.01 AUD
Jan 1, 2012
0 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2013
0 AUD
-0.05 AUD
-0.07 AUD
Jan 1, 2014
0 AUD
-0.03 AUD
-0.15 AUD
Jan 1, 2015
0.01 AUD
-0.01 AUD
-0 AUD
Jan 1, 2016
0.02 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2017
0.04 AUD
-0.03 AUD
-0.03 AUD
Jan 1, 2018
0.29 AUD
-0.18 AUD
-0.18 AUD
Jan 1, 2019
0.05 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2020
0.05 AUD
-0.04 AUD
-0.04 AUD
Jan 1, 2021
0.13 AUD
-0.05 AUD
-0.04 AUD
Jan 1, 2022
0.18 AUD
-0.04 AUD
-0.05 AUD
Jan 1, 2023
0.18 AUD
-0.02 AUD
-0.02 AUD
Jan 1, 2024
0.18 AUD
-0 AUD
0 AUD
Jan 1, 2025
0.11 AUD
-0.02 AUD
-0.11 AUD

MedAdvisor business model & stock analysis

Medadvisor Ltd is an Australian company that offers a digital platform for healthcare. Founded in 2012 by Robert Read, David Liu, and Josh Swinnerton, their aim was to develop a platform that simplifies medication management for patients, pharmacies, and doctors. Today, Medadvisor is a publicly traded company with a wide range of digital healthcare solutions. They offer various solutions to support patients in medication intake and management, such as a mobile application that allows patients to manage their medications, order prescriptions, and receive reminders. They also offer solutions for pharmacies, including an online ordering system and access to electronic patient history, as well as a platform for doctors to electronically issue prescriptions. One of their latest products is a mobile application that facilitates the handling of COVID-19, providing real-time virus spread tracking and symptom tracking tools. Medadvisor focuses on meeting customer needs and continuously improving the healthcare process. They recently partnered with Take2 Healthcare to expand their range of solutions and create the best offering of health solutions. Overall, Medadvisor plays an important role in the Australian healthcare system by helping their customers live happier and healthier lives through innovative technologies and services.

MedAdvisor SWOT Analysis

Strengths

Medadvisor Ltd has a strong market presence in the healthcare industry, particularly in medication management.

The company has developed a user-friendly and innovative platform that enables patients to have better control over their medications.

Medadvisor's technology has the capability to integrate with existing systems, providing seamless integration for healthcare providers.

Weaknesses

Medadvisor relies heavily on partnerships with pharmaceutical companies and healthcare providers, creating a vulnerability to changes in these relationships.

The company has a relatively small market share and faces strong competition from established players in the industry.

Medadvisor's platform requires patients to actively engage and adopt the technology, which may pose a challenge in convincing a wider audience to use the service.

Opportunities

There is a growing demand for digital healthcare solutions, especially in the medication management space, presenting opportunities for Medadvisor to expand its user base.

The COVID-19 pandemic has accelerated the adoption of telehealth and remote patient monitoring, which aligns with Medadvisor's capabilities and opens up new market segments.

Expansion into international markets, where medication management solutions are not as well-developed, can help Medadvisor tap into new revenue streams.

Threats

Competitors may develop similar or superior medication management platforms, eroding Medadvisor's market share.

Changes in healthcare regulations and reimbursement policies could impact the adoption and utilization of Medadvisor's services.

Data privacy and security concerns may discourage potential users from adopting Medadvisor's platform, especially in light of increasing cyber threats.

MedAdvisor Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

MedAdvisor historical P/E ratio, EBIT multiple, and P/S ratio

MedAdvisor annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

MedAdvisor shares outstanding

The number of shares was MedAdvisor in 2025 — This indicates how many shares 565.564 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2011
7.37 M base_Shares
Jan 1, 2012
25.43 M base_Shares
Jan 1, 2013
54.76 M base_Shares
Jan 1, 2014
73.4 M base_Shares
Jan 1, 2015
120.51 M base_Shares
Jan 1, 2016
81.14 M base_Shares
Jan 1, 2017
124.86 M base_Shares
Jan 1, 2018
25.35 M base_Shares
Jan 1, 2019
194.31 M base_Shares
Jan 1, 2020
231.93 M base_Shares
Jan 1, 2021
316.51 M base_Shares
Jan 1, 2022
378.12 M base_Shares
Jan 1, 2023
544.96 M base_Shares
Jan 1, 2024
548.12 M base_Shares
Jan 1, 2025
565.56 M base_Shares
Price targets and forecasts for MedAdvisor are not yet available.

MedAdvisor shareholder structure

% Name
16.78062%
Guild Group Holdings, Ltd.
Guild Group Holdings, Ltd.
15.88393%
Perennial Value Management Ltd.
Perennial Value Management Ltd.
9.5456%
EBOS PH Pty. Ltd.
EBOS PH Pty. Ltd.
9.26331%
Jencay Capital Pty Ltd
Jencay Capital Pty Ltd
7.77984%
Cotiviti, Inc.
Cotiviti, Inc.
4.4602%
Mercer Investments (Australia) Limited
Mercer Investments (Australia) Limited
3.88992%
Herald Investment Management Limited
Herald Investment Management Limited
2.91285%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
1.21822%
Xenos (Jim)
Xenos (Jim)
1.15814%
Indcorp Consulting Group Pty. Ltd.
Indcorp Consulting Group Pty. Ltd.

Frequently asked questions about MedAdvisor

The business model of Medadvisor Ltd revolves around providing digital health solutions and medication management services. Medadvisor operates a cloud-based platform that aims to empower patients, pharmacies, and healthcare providers with tools to enhance medication adherence and improve health outcomes. Through its mobile app and web-based portal, Medadvisor offers features such as medication reminders, prescription management, health record access, and medication ordering. The company generates revenue through subscription fees paid by pharmacies and healthcare providers, as well as transactional fees from medication orders. Medadvisor aims to transform the healthcare industry by leveraging technology to streamline medication management and enhance patient engagement.

All fundamentals and in-depth analysis of MedAdvisor

Our stock analysis for MedAdvisor Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MedAdvisor Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.